R&D
Pairing a ‘Smart Bomb’ Drug With a PARP Blocker Hit Lung Cancer Harder in Lab Tests
Combining an antibody-drug conjugate with the PARP inhibitor olaparib overwhelmed non-small cell lung cancer’s DNA-repair defenses — and roused the immune system — in preclinical models.